Qiagen Toekomstige groei
Future criteriumcontroles 1/6
Qiagen zal naar verwachting groeien in winst en omzet met respectievelijk 12.4% en 6.1% per jaar. De winst per aandeel zal naar verwachting groeien met 11.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.4% zijn.
Belangrijke informatie
12.4%
Groei van de winst
11.91%
Groei van de winst per aandeel
| Life Sciences winstgroei | 17.6% |
| Inkomstengroei | 6.1% |
| Toekomstig rendement op eigen vermogen | 13.41% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...Analyseartikel • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...Recent updates
Nieuw narratief • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.Narratiefupdate • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.Narratiefupdate • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.Narratiefupdate • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.Narratiefupdate • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.Narratiefupdate • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.Narratiefupdate • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Seeking Alpha • Jan 27
Qiagen: Takeover Optionality With A High-Quality Consumables Platform
Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking AlphaNarratiefupdate • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).Analyseartikel • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...Narratiefupdate • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.Narratiefupdate • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.Narratiefupdate • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.Analyseartikel • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...Narratiefupdate • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.Narratiefupdate • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.Narratiefupdate • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.Narratiefupdate • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.Analyseartikel • Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...Analyseartikel • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...Analyseartikel • Aug 05
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...Seeking Alpha • Feb 25
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking AlphaWinst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 2,406 | 572 | 557 | 783 | 12 |
| 12/31/2027 | 2,272 | 467 | 529 | 743 | 16 |
| 12/31/2026 | 2,155 | 406 | 495 | 705 | 16 |
| 3/31/2026 | 2,099 | 402 | 404 | 615 | N/A |
| 12/31/2025 | 2,090 | 425 | 447 | 654 | N/A |
| 9/30/2025 | 2,071 | 405 | 473 | 658 | N/A |
| 6/30/2025 | 2,040 | 373 | 496 | 675 | N/A |
| 3/31/2025 | 2,003 | 94 | 503 | 680 | N/A |
| 12/31/2024 | 1,978 | 84 | 502 | 674 | N/A |
| 9/30/2024 | 1,966 | 93 | 460 | 633 | N/A |
| 6/30/2024 | 1,940 | 73 | 405 | 576 | N/A |
| 3/31/2024 | 1,939 | 337 | 358 | 521 | N/A |
| 12/31/2023 | 1,965 | 341 | 297 | 459 | N/A |
| 9/30/2023 | 1,954 | 332 | 275 | 432 | N/A |
| 6/30/2023 | 1,978 | 337 | 376 | 519 | N/A |
| 3/31/2023 | 1,999 | 353 | 430 | 580 | N/A |
| 12/31/2022 | 2,142 | 423 | 566 | 715 | N/A |
| 9/30/2022 | 2,226 | 488 | 660 | 826 | N/A |
| 6/30/2022 | 2,261 | 539 | 580 | 770 | N/A |
| 3/31/2022 | 2,313 | 563 | 556 | 755 | N/A |
| 12/31/2021 | 2,252 | 513 | 432 | 639 | N/A |
| 9/30/2021 | 2,240 | 311 | 516 | 745 | N/A |
| 6/30/2021 | 2,190 | 480 | 337 | 592 | N/A |
| 3/31/2021 | 2,065 | 449 | 239 | 571 | N/A |
| 12/31/2020 | 1,870 | 359 | 154 | 458 | N/A |
| 9/30/2020 | 1,713 | 191 | 10 | 298 | N/A |
| 6/30/2020 | 1,612 | 14 | 108 | 333 | N/A |
| 3/31/2020 | 1,550 | -31 | 152 | 302 | N/A |
| 12/31/2019 | 1,526 | -41 | N/A | 331 | N/A |
| 9/30/2019 | 1,516 | -25 | N/A | 332 | N/A |
| 6/30/2019 | 1,511 | 196 | N/A | 342 | N/A |
| 3/31/2019 | 1,507 | 188 | N/A | 356 | N/A |
| 12/31/2018 | 1,502 | 190 | N/A | 359 | N/A |
| 9/30/2018 | 1,496 | 90 | N/A | 325 | N/A |
| 6/30/2018 | 1,482 | 78 | N/A | 324 | N/A |
| 3/31/2018 | 1,453 | 55 | N/A | 275 | N/A |
| 12/31/2017 | 1,418 | 40 | N/A | 287 | N/A |
| 9/30/2017 | 1,387 | 89 | N/A | 311 | N/A |
| 6/30/2017 | 1,362 | 75 | N/A | 323 | N/A |
| 3/31/2017 | 1,347 | 82 | N/A | 353 | N/A |
| 12/31/2016 | 1,338 | 80 | N/A | 342 | N/A |
| 9/30/2016 | 1,320 | 123 | N/A | 328 | N/A |
| 6/30/2016 | 1,296 | 123 | N/A | 331 | N/A |
| 3/31/2016 | 1,281 | 126 | N/A | 303 | N/A |
| 12/31/2015 | 1,281 | 130 | N/A | 317 | N/A |
| 9/30/2015 | 1,293 | 104 | N/A | 310 | N/A |
| 6/30/2015 | 1,315 | 105 | N/A | 303 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei QGEN ( 12.4% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van QGEN ( 12.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.8% per jaar).
Hoge groeiwinsten: De winst van QGEN zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van QGEN ( 6.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).
Hoge groei-inkomsten: De omzet van QGEN ( 6.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen QGEN zal naar verwachting over 3 jaar laag zijn ( 13.4 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/24 22:26 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Qiagen N.V. wordt gevolgd door 42 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |